We found molecular markers in addition to cyclin D1 and characteristic antigens (shared with blood cells from which the tumor may develop) CD5, CD20 and FMC7 with the aim to better delineate the regulatory network regulated differently in MCL. This evidence concerns the gene MS4A1 and mantle cell lymphoma.